Other
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst
Executive Summary
- Latest Release (May 6, 2026): Eupraxia Pharmaceuticals released sub-score data from its ongoing Phase 1b/2a RESOLVE trial at Digestive Disease Week (DDW). The data focuses on the EoEHSS (Eosinophilic Esophagitis Histology Scoring System), specifically inflammation (EoEHSS-i) and fibrosis/architecture (EoEHSS-a).
- Key Findings: In the highest dose cohort (Cohort 9, 20x8mg), patients showed >90% improvement in inflammation grade/stage and >83% improvement in fibrosis grade/stage at both 12 and 36 weeks.
- Contextual Progression: This follows a sequence of positive data releases:
- Jan 8, 2026: Tissue health data showing near-complete normalization.
- Apr 21, 2026: Nine-month symptom and tissue health data from Cohort 9 (66% remission rate).
- May 5, 2026: EREFS endoscopic data confirming dose-response relationship.
- Trial Status: The Phase 2b randomized placebo-controlled portion is recruiting for the 120mg and 160mg doses. Top-line results expected Q4 2026.
- Financial Context: Q4 2025 results (March 12, 2026) showed $80.5M cash on hand following a $63.2M public offering in Feb 2026. Runway extends to H2 2028.
Material Impact
- Rating Justification: The news is categorized as Routine - Positive. While the clinical data (>90% fibrosis improvement) is robust, it was presented at DDW (May 2-5), and a press release followed immediately on May 6. Investors tracking the trial progression from Jan through April would have anticipated this specific sub-score confirmation.
- Market Expectations: The market has already priced in the positive trajectory established by the January tissue health data and the April symptom durability data. This release validates the mechanism of action (fibrosis reversal) but does not introduce a new indication, partnership, or regulatory approval milestone that would fundamentally alter the valuation model overnight.
- Risk Aversion: The binary risk remains with Phase 2b results in Q4 2026. While this data de-risks the mechanism slightly, it is part of an open-label dose-escalation study (Phase 1b/2a), which carries less weight than a randomized placebo-controlled readout.
- Price Action: The stock has corrected from its January high ($12.50) to current levels (~$9.88). This news may provide support but is unlikely to trigger a significant breakout without the Phase 2b catalyst.
EPRX · Price
Company Overview
- Company: Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on gastrointestinal diseases.
- Flagship Project: EP-104GI (Fluticasone Propionate). It is a long-acting submucosal corticosteroid formulation designed for local delivery via injection into esophageal tissues.
- Indication: Eosinophilic Esophagitis (EoE), with potential expansion to fibrostenotic Crohn’s disease and benign esophageal strictures.
- Mechanism: Unlike oral steroids, EP-104GI is injected directly into the tissue to reduce inflammation and fibrosis without systemic side effects (e.g., adrenal insufficiency).
More from EUPRAXIA PHARMACEUTICALS INC. J
May 12, 2026 · 17:00